Intestinal symptoms are common after hematopoietic SCT (HSCT). In this setting, differential diagnosis specifically for diarrhea includes infections, conditioning regimen toxicity and intestinal GVHD (IGVHD), among others. The importance of an early and accurate diagnosis lies in the different therapeutic approaches, outcome and prognosis. The gold standard for the diagnosis of acute IGVHD is endoscopy, 1 which sometimes yields non-specific findings and is an invasive procedure, 2 and histological confirmation with the demonstration of intracryptal apoptosis. 3 Calprotectin is a major protein found in the cytosol of inflammatory cells, especially granulocytes. It represents about half of the cytosol of neutrophils and is also present in macrophages. 4 The protein has two subunits and belongs to the family of S100 proteins. It is stable at room temperature and can be measured in stool with ELISA test in a few hours. Fecal calprotectin (FC) was introduced in clinical practice for the differential diagnosis between functional gastrointestinal diseases and disorders with mucosal inflammation. Several studies have demonstrated the utility of this simple non-invasive and inexpensive test for these diseases. 5, 6 In the same way, it has been used with encouraging results in patients with small bowel transplantation for the differential diagnosis of intestinal graft rejection. 7, 8 Our aim was to evaluate FC for the diagnosis of acute IGVHD in patients with diarrhea following allogeneic HSCT.
This was a prospective study sponsored by the GVHD Subcommittee of the Spanish GETH and was carried out between March 2009 and March 2011 at two University hospitals; Hospital La Paz, Madrid and Hospital Morales Meseguer, Murcia. The study was approved by the Institutional Review Board of Hospital La Paz. The inclusion criteria were as follows: patients who presented with diarrhea and suspicion of acute IGVHD after allogeneic HSCT were consecutively included. Patients included were tested for FC using a commercial quantitative ELISA (Calprest, Eurospital SpA, Trieste, Italy) according to the manufacturer's instructions (reference range: 0 --50 mg/kg) within 48 h after the development of symptoms, before starting empiric treatment for GVHD. Other stool studies, including Clostridium difficile toxins A and B, cultures and intestinal parasites examinations were also performed. Blood samples were tested for CMV by quantitative CMV --PCR and pp65-Ag. Colonoscopy was performed in all patients (upper gastrointestinal endoscopy was not required for the study because FC level is not influenced by upper gastrointestinal inflammation). All patients were histologically and endoscopically graded with the validated Freiburg criteria, 9 despite the final diagnosis. When lesions were seen, biopsies were taken from the lesions for histopathological examination and immunohistochemistry for CMV. When colonoscopy was normal random biopsies were taken from the ascending colon, transverse colon and rectum.
A total of 23 patients were included. Median age was 44 years (range: 32 --57). The median time from the stem cells infusion to the development of symptoms was 52 days (range: 13 --97). All patients presented with diarrhea; other symptoms were fever, anorexia, nausea and vomiting. There were no patients with isolated upper GI symptoms. Patient characteristics are summarized in Table 1 . In all, 11 patients were diagnosed with acute IGVHD. FC median value in patients with IGVHD was 504.83 mg/kg (95% confidence interval (CI): 391.4 --618.26) and FC median value in patients with other diagnosis than IGVHD was 123.25 mg/kg (95% CI: 45.1 --201.34) (Po0.001). Figure 1 summarizes the distribution of FC values in each of the two groups.
There were five patients diagnosed with CMV colitis (positive immunohistochemistry) and one of them also had concomitant IGVHD. In the four patients diagnosed with isolated CMV colitis, The FC was higher in patients with IGVHD histological stage 3 --4, with a median value of 602.13 mg/kg (range: 502 --649) compared with IGVHD grades 1 --2, with a median value of 274.3 mg/kg (107 --415) (Po0.001). For a cut-off point value of 250 mg/kg, sensitivity for the test was 83.3% (95% CI: 61.3-100%), specificity 90.9%, positive predictive value 83.3% and negative predictive value 90.9% (95% CI: 61.3 --100%). Under a cut-off value of 100 mg/kg, the negative predictive value for the test was 100% and for a cut-off value over 450, the positive predictive value was 100%. The area under the ROC curve for the test was 0.96 (95% CI: 0.89 --1.03).
In the HSCT setting, it is clinically difficult to distinguish between gastrointestinal disorders like acute IGVHD, severe infections and non-specific inflammation because they all display similar symptoms such as diarrhea and fever. However, it is essential to differentiate these entities because they need different treatment. At present, the gold standard for the diagnosis of GVHD is endoscopy with biopsies. Unfortunately there is no specific non-invasive test available to differentiate these conditions. 10 Since the past decade, it has been shown that FC correlates very well with disease activity in patients with inflammatory bowel disease as well as in patients with intestinal graft rejection, preventing the necessity of colonoscopy in a significant number of patients. This study shows that FC could be a useful non-invasive test for the diagnosis of acute IGVHD. Statistical analysis was plotted to determine the optimal cut-off level of calprotectin. A level of FC under 250 mg/kg had very interesting numbers of specificity and sensitivity with a really high negative predictive value for the diagnosis of IGVHD. In addition, FC was below 100 mg/kg in all patients without GVHD (negative predictive value of 100%). Despite patients with CMV infection who had abnormal level of calprotectin, the cut-off value of 250 mg/kg could differentiate between CMV infection and IGVHD. It is important to mention that FC is only useful in patients with colonic involvement, and it has no role in isolated upper gastrointestinal disease.
In conclusion, FC appears to be a promising non-invasive biomarker of acute IGVHD. If these encouraging findings are confirmed in a larger number of patients, it may provide a noninvasive test for the diagnosis of acute IGVHD. 
